Synthetic enzyme - PvP Biologics

Drug Profile

Synthetic enzyme - PvP Biologics

Alternative Names: KumaMax

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Washington
  • Developer PvP Biologics
  • Class Enzymes; Proteins
  • Mechanism of Action Gliadin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Coeliac disease

Most Recent Events

  • 05 Jan 2017 PvP Biologics and Takeda collaborate to develop synthetic enzyme for Coeliac disease
  • 20 Dec 2016 Preclinical trials in Coeliac disease in USA (PO)
  • 20 Dec 2016 PvP Biologics plans clinical trial for Coeliac disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top